Clinical and histologic evaluation of granular Beta-tricalcium phosphate for the treatment of human intrabony periodontal defects: a report on five cases.
BACKGROUND
The aim of the study is to clinically and histologically evaluate the healing of advanced intrabony defects treated with open flap debridement and the adjunct implantation of granular beta tricalcium phosphate (beta-TCP).


METHODS
Five patients, each displaying advanced combined 1- and 2-wall intrabony defects around teeth scheduled for extraction or root resection, were recruited. Approximately 6 months after surgery, the teeth or roots were removed together with a portion of their surrounding soft and hard tissues and processed for histologic evaluation.


RESULTS
The mean probing depth (PD) was reduced from 10.8 +/- 2.3 mm presurgically to 4.6 +/- 2.1 mm, whereas a mean clinical attachment level (CAL) gain of 5.0 +/- 0.7 mm was observed. The increase in gingival recession was 1.2 +/- 3.2 mm. The histologic evaluation indicated the formation of new cellular cementum with inserting collagen fibers to a varying extent (mean: 1.9 +/- 0.7 mm; range: 1.2 to 3.03 mm) coronal to the most apical extent of the root instrumentation. The mean new bone formation was 1.0 +/- 0.7 mm (range: 0.0 to 1.9 mm). In most specimens, beta-TCP particles were embedded in the connective tissue, whereas the formation of a mineralized bone-like or cementum-like tissue around the particles was only occasionally observed.


CONCLUSIONS
The present data indicates that treatment of intrabony periodontal defects with this beta-TCP may result in substantial clinical improvements such as PD reduction and CAL gain, but this beta-TCP does not seem to enhance the regeneration of cementum, periodontal ligament, and bone.
Stavropoulos
Andreas
A
Department of Periodontology, School of Dentistry, University of Aarhus, Aarhus, Denmark. stavropoulos@odont.au.dk
Windisch
Péter
P
Szendröi-Kiss
Dora
D
Peter
Rosta
R
Gera
István
I
Sculean
Anton
A
D016301:Alveolar Bone Loss / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D018786:Bone Substitutes / Q000627:therapeutic use*; D002130:Calcium Phosphates / Q000627:therapeutic use*; D055113:Chronic Periodontitis / Q000150:complications / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003646:Debridement; D003739:Dental Cementum / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D016348:Osseointegration / Q000187:drug effects; D010513:Periodontal Ligament / Q000187:drug effects; D016896:Treatment Outcome
D018786:Bone Substitutes; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate